<DOC>
	<DOCNO>NCT00002188</DOCNO>
	<brief_summary>The purpose study see ALRT1057 safe effective treating patient AIDS-related Kaposi 's sarcoma ( KS ) .</brief_summary>
	<brief_title>A Study ALRT1057 Patients With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>Patients receive open-label ALRT1057 16 week , tolerate . In absence unacceptable toxicity , patient may continue treatment indefinitely provide continue benefit therapy study remain open active . Thirteen patient treat initially . If least one response observe patient , 14 additional patient evaluate .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV positive status histologic confirmation KS . CD4 count &gt; 200 mm3 ( require onehalf patient ) . Minimum 6 mucocutaneous KS lesion , include least 3 raise lesion meeting criterion `` indicator '' lesion . Acceptable organ system function . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Serious intercurrent illness infection would interfere ability patient carry treatment program . Prior Medication : Excluded : Systemic therapy KS within 30 day . Local topical therapy KS indicative lesion within 60 day . Systemic therapy vitamin A dose exceed 15,000 IU per day retinoid class drug . Required : Approved antiretroviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Antineoplastic Agents</keyword>
</DOC>